


SELECTED CLINICAL RESEARCH PROTOCOLS FOR BREAST CANCER



Surgical Oncology

NSABP-B-32 Phase III Randomized Study of Sentinel Node Dissection With or Without Conventional Axillary Dissection in Women With Clinically Node Negative Breast Cancer

Chairperson: David N. Krag. Telephone: 802-656-5830. Lead organization: National Surgical Adjuvant Breast and Bowel Project. Age range: not specified.

ACOSOG-Z0011, GUMC-00153 Phase III Randomized Study of Axillary Lymph Node Dissection in Women With Stage I or IIA Breast Cancer Who Have a Positive Sentinel Node

Chairperson: Armando E. Giuliano. Telephone: 310-829-8089. Lead organization: American College of Surgeons Oncology Group. Age range: over 18.

ACOSOG-Z0010, GUMC-00152 Phase III Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women With Stage I or IIA Breast Cancer

Chairperson: Armando E. Giuliano. Telephone: 310-829-8089. Lead organization: American College of Surgeons Oncology Group. Age range: Over 18.

MCC-12114, NCI-G00-1808, MCC-IRB-5499 Diagnostic Randomized Study of Radioactive Seed Localized Breast Biopsy Versus Needle Localized Breast Biopsy in Patients With Nonpalpable Breast Lesions

Chairperson: Charles E. Cox. Telephone: 813-972-8480. Lead organization: H. Lee Moffitt Cancer

Center & Research Institute. Age range: 18 and over.

Radiation Therapy

RTOG-9804, CTSU, RTOG-DEV-1026 Phase III Randomized Study of Tamoxifen With or Without Radiotherapy in Women With Ductal Carcinoma In Situ (DCIS) of the Breast

Chairperson: Beryl McCormick. Telephone: 212-639-6828. Lead organization: Radiation Therapy Oncology Group. Age range: 26 and over.

SWOG-S9927, GUMC-00223 Phase III Randomized Study of Postmastectomy Radiotherapy in Women With Stage II Breast Cancer With One to Three Positive Nodes

Chairperson: Lori J. Pierce. Telephone: 734-936-7810. Lead organization: Southwest Oncology Group. Age range: 21 and over.

CAN-NCIC-MA20 Phase III Randomized Study of Adjuvant Breast Radiotherapy With or Without Regional Radiotherapy in Women With Resected, Early Stage, Invasive Breast Cancer

Chairperson: Timothy Joseph Whelan. Telephone: 905-387-9711. Lead organization: NCIC-Clinical Trials Group. Age range: 16 and over.

Systemic Therapy

Infiltrating Cancer

SWOG-S9905 Phase III Randomized Study of Zoledronate as

This list of clinical research protocols relating to breast cancer is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at <http://cancer.net.nci.nih.gov/trialsrch.shtml>.

A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

Adjuvant Therapy in Patients With Stage I, II, or IIIA Nonmetastatic Breast Cancer

Chairperson: Charles A. Coltman, Jr. Telephone: 210-616-5580. Lead organization: Southwest Oncology Group. Age range: not specified.

SWOG-S9630, SWOG-9630

Phase III Randomized Study of Medroxyprogesterone Acetate and Observation for Prevention of Endometrial Pathology in Patients With Postmenopausal Breast Cancer Treated With Adjuvant Tamoxifen

Chairperson: Ronald Keith Potkul. Telephone: 708-327-3314. Lead organization: Southwest Oncology Group. Age range: 18 and over.

CAN-NCIC-MA21, AMGEN-CAN-NCIC-MA21, BMS-CAN NCIC-MA21, JANSSEN-CAN-NCIC-MA21, P-UPJOHN-CAN-NCIC-MA21

Phase III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin and Fluorouracil Versus Cyclophosphamide, Epirubicin, Filgrastim (G-CSF), and Epoetin Alfa Followed By Paclitaxel Versus Cyclophosphamide and Doxorubicin Followed By Paclitaxel in Premenopausal or Early Postmenopausal Women With Previously Resected Node Positive or High-Risk Node Negative Stage I-IIIa Breast Cancer

Chairperson: Margot J. Burnell. Telephone: 506-648-6884. Lead organization: NCIC-Clinical Trials Group. Age range: 60 and under.

CAN-NCIC-MA17, CLB-49805, EORTC-10983, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17 Phase III Randomized Study of Letrozole Versus Placebo in

Women With Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Tamoxifen

Chairperson: Paul Edward Goss. Telephone: 416-946-4534. Lead organization: NCIC-Clinical Trials Group. Age range: postmenopausal.

NSABP-B-33, CTSU Phase III Randomized Study of Exemestane in Postmenopausal Women With Resected Stage I, II, or IIIa Breast Cancer Who Have Completed Five Years of Tamoxifen

Chairperson: Terry Mamounas. Telephone: 330-363-6281. Lead organization: National Surgical Adjuvant Breast and Bowel Project. Age range: postmenopausal.

Trastuzumab Studies

NCCTG-N9831, GUMC-00224 Phase III Randomized Study of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab (Herceptin) in Patients With HER-2 Overexpressing Breast Cancer

Chairperson: Edith A. Perez. Telephone: 904-953-7283. Lead organization: North Central Cancer Treatment Group. Age range: 18 and over.

CLB-49808, CTSU Phase III Randomized Study of Doxorubicin and Cyclophosphamide With or Without Dexrazoxane, Followed by Paclitaxel With or Without Trastuzumab (Herceptin), Followed By Surgery and Radiotherapy With or Without Trastuzumab in Women With HER-2+ Stage IIIa or IIIB or Regional Stage IV Breast Cancer

Chairperson: Mark L. Graham. Telephone: 919-859-6631. Lead or-

ganization: Cancer and Leukemia Group B. Age range: 18 and over.

NSABP-B-31 Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab (Herceptin) in Women With Node Positive Breast Cancer That Overexpresses HER2

Chairperson: Edward H. Romond. Telephone: 859-323-8043. Lead organization: National Surgical Adjuvant Breast and Bowel Project. Age range: not specified.

Metastatic Disease

AVENTIS-56976-TAX-311, NCI-V95-0680, RP-56976-TAX-311

Phase III Randomized Study of Docetaxel Versus Paclitaxel in Women With Metastatic or Locally Advanced, Inoperable Adenocarcinoma of the Breast

Chairperson: Peter Marcus Ravdin. Telephone: 210-567-4777. Lead organization: Aventis Pharmaceuticals, Inc. Age range: 18 and over.

GENENTECH-AVF2119g, GUMC-00299 Phase III Randomized Study of Bevacizumab With Capecitabine Versus Capecitabine Alone in Women With Previously Treated Metastatic Breast Cancer

Chairperson: Ginny Langmuir. Telephone: 650-225-4985. Lead organization: Genentech Inc. Age range: 18 and over.

Cancer Control

E-1Y92, NCI-P93-0042 Randomized Study of Brief Physician-

Initiated Smoking Cessation Strategies Versus Usual Care in Patients With Early Stage Cancer Who are Undergoing Treatment in Clinical Oncology Settings

Chairperson: Neal Richard Boyd, Jr. Telephone: 215-728-6900. Lead organization: Eastern Cooperative Oncology Group. Age range: 19 and over.

Chairperson: Norman Wolmark. Telephone: 412-359-3336. Lead organization: National Surgical Adjuvant Breast and Bowel Project. Age range: 35 and over.

SJHCH-TM1, NCI-V00-1618

Randomized Study of Stress Reduction in Older Women With Stage II, III, or IV Breast Cancer

Chairperson: Rhoda Pomerantz. Telephone: 773-665-3606. Lead organization: St. Joseph Hospital. Age range: 55 and over.

ACRIN-6652 Screening and Diagnostic Study of Digital Mammography Versus Screen-Film Mammography in the Detection of Breast Cancer in Women

Chairperson: Bruce J. Hillman. Telephone: 804-982-0211. Lead organization: American College of Radiology Imaging Network. Age range: any age.

E-5194 Screening Study Following Local Excision in Selected Patients With Ductal Carcinoma In Situ (DCIS) of the Breast

Chairperson: Lorie L. Hughes. Telephone: 404-233-4960. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

Prevention

NSABP-P-2 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer